4//SEC Filing
TANG KEVIN C 4
Accession 0001209191-20-048868
CIK 0001717452other
Filed
Aug 31, 8:00 PM ET
Accepted
Sep 1, 8:17 AM ET
Size
11.8 KB
Accession
0001209191-20-048868
Insider Transaction Report
Form 4
TANG CAPITAL PARTNERS LP
10% Owner
Transactions
- Purchase
Common Stock
2020-08-28$14.25/sh+1,052,631$14,999,992→ 15,127,900 total(indirect: By LP)
TANG CAPITAL MANAGEMENT LLC
10% Owner
Transactions
- Purchase
Common Stock
2020-08-28$14.25/sh+1,052,631$14,999,992→ 15,127,900 total(indirect: By LP)
Lemkey John G
Chief Financial Officer
Transactions
- Purchase
Common Stock
2020-08-28$14.25/sh+1,052,631$14,999,992→ 15,127,900 total(indirect: By LP)
Hearne Michael S
Chief Financial Officer
Transactions
- Purchase
Common Stock
2020-08-28$14.25/sh+1,052,631$14,999,992→ 15,127,900 total(indirect: By LP)
TANG KEVIN C
DirectorChief Executive Officer10% Owner
Transactions
- Purchase
Common Stock
2020-08-28$14.25/sh+1,052,631$14,999,992→ 15,127,900 total(indirect: By LP)
Footnotes (1)
- [F1]The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. John Lemkey is the Chief Operating Officer of Odonate Therapeutics, Inc., as well as Chief Operating Officer of TCM. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang, Mr. Lemkey and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP.
Documents
Issuer
Odonate Therapeutics, Inc.
CIK 0001717452
Entity typeother
Related Parties
1- filerCIK 0001178579
Filing Metadata
- Form type
- 4
- Filed
- Aug 31, 8:00 PM ET
- Accepted
- Sep 1, 8:17 AM ET
- Size
- 11.8 KB